M
Monique A. Hartley-Brown
Publications - 6
Citations - 45
Monique A. Hartley-Brown is an academic researcher. The author has contributed to research in topics: Multiple myeloma & Internal medicine. The author has an hindex of 2, co-authored 2 publications receiving 34 citations.
Papers
More filters
Journal ArticleDOI
Quantification of peptides from immunoglobulin constant and variable regions by LC‐MRM MS for assessment of multiple myeloma patients
Elizabeth R. Remily-Wood,Kaaron Benson,Rachid Baz,Y. Ann Chen,Mohamad A. Hussein,Monique A. Hartley-Brown,Robert Sprung,Brianna Perez,Richard Z. Liu,Sean J. Yoder,Jamie K. Teer,Steven A. Eschrich,John M. Koomen +12 more
TL;DR: Quantitative MS assays for Igs are compared with existing clinical methods in samples from patients with plasma cell dyscrasias, for example, multiple myeloma (MM).
Journal ArticleDOI
State-of-the-Art Management of Complications of Myeloma and Its Treatment.
TL;DR: The effects of myeloma and the novel therapies on organ systems are reviewed and management strategies are suggested based on anecdotal experience.
Journal ArticleDOI
Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?
TL;DR: A look at the current ADCs being tested in MM clinical trials with a focus on those that are more promising and a potential next-in-line for FDA approval for treatment of MM is discussed.
Journal ArticleDOI
Selinexor: Targeting a novel pathway in multiple myeloma
Clifton C. Mo,Andrew Yee,Shonali Midha,Monique A. Hartley-Brown,Omar Nadeem,Elizabeth O'Donnell,Giada Bianchi,Adam S. Sperling,Jacob P. Laubach,Paul G. Richardson +9 more
TL;DR: Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin-1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nuclear proteins to the cytoplasm, including tumour suppressor proteins as discussed by the authors .
Journal ArticleDOI
P-006: Real world experience of patients treated with idecabtagene vicleucel: a BCMA-directed chimeric antigen receptor T-cell therapy for multiple myeloma
Dalton Canonico,Jacob P. Laubach,Clifton C. Mo,Adam S. Sperling,Sarah Nikiforow,Robert A. Redd,Linda A. Ramsdell,Kathleen McDermott,Kathleen T. Finn,Lauren Desnoyers,Caron A. Jacobson,Giada Bianchi,Shonali Midha,Monique A. Hartley-Brown,Irene M. Ghobrial,Kenneth C. Anderson,Nikhil C. Munshi,Omar Nadeem +17 more